Free Trial
NASDAQ:GPCR

Structure Therapeutics Q4 2024 Earnings Report

Structure Therapeutics logo
$23.74 +0.09 (+0.38%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$22.79 -0.95 (-4.00%)
As of 04/25/2025 07:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Structure Therapeutics EPS Results

Actual EPS
-$0.22
Consensus EPS
-$0.23
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Structure Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Structure Therapeutics Announcement Details

Quarter
Q4 2024
Time
After Market Closes
Conference Call Date
Thursday, February 27, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Structure Therapeutics' Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled on Friday, May 9, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Structure Therapeutics Earnings Headlines

Structure Therapeutics' (GPCR) Buy Rating Reaffirmed at HC Wainwright
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.
See More Structure Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Structure Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Structure Therapeutics and other key companies, straight to your email.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR), a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

View Structure Therapeutics Profile

More Earnings Resources from MarketBeat